Safety and Pharmacokinetics of NP10679 in Normal Healthy Volunteers

Completed · Phase 1 · Has a placebo group

Conditions studied: Safety Issues

In brief

This study assesses the safety, tolerability and pharmacokinetics of NP10679 when delivered intravenously in escalating dose levels in comparison to placebo.

Key facts

Study ID

NCT03565861

Run by

Neurop Inc.

People needed

48

Starts

2018-04-06

Expected to finish

2018-10-10

Last updated by the study team

2019-03-13

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male and female subjects aged 18 to 55 years
• Ability to understand the requirements of the study, provide written informed consent, abide by the study restrictions, and agree to return for the required assessments.
• If of child bearing potential (both men and women) must agree to use 2 forms of contraceptive methods for the duration of study.

You may not qualify if…

• Clinical laboratory values greater than or equal to 2 times the upper limit of normal.
• Recent history (within 2 yrs) or current tobacco use.

Where it is running

• Pharmaron CPC — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.